Ataxin 1 Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Ataxin-1 (ATXN1) is a nuclear protein encoded by the ATXN1 gene. Pathogenic expansion of a CAG repeat causes Spinocerebellar Ataxia type 1 (SCA1), and ATXN1 is implicated in other neurodegenerative diseases including Alzheimer's disease.
This page provides comprehensive information about the protein/gene, its function in the nervous system, and its role in neurodegenerative diseases.
Ataxin-1 is an 816 amino acid protein with several functional domains:
- AXH domain (565-816): Aromatic residue-rich, hydrophobic, X = any residue - mediates homomerization and RNA binding
- Nuclear localization signal (NLS): KKKVK ( residues 305-309)
- Phosphorylation sites: Serine 776 (S776) - critical for toxicity
- Protein interactions: MINT1/X11, LANP, Ref1(2)
- Molecular weight: ~87 kDa
- Normal: 6-35 CAG repeats
- Pathogenic: 41-81+ repeats
- Expanded polyglutamine (polyQ) tract confers toxicity
Ataxin-1 is primarily nuclear and enriched in Purkinje cells:
- Transcriptional Regulation: Binds to transcription factors, modulates gene expression
- RNA Processing: Associates with RNA splicing machinery
- Neuronal Development: Critical for cerebellar development
- Synaptic Plasticity: Regulates synaptic strength and structure
- Highest in cerebellum (especially Purkinje cells)
- Broad expression in CNS
- Nuclear and cytoplasmic localization
- Autosomal dominant trinucleotide repeat disorder
- Progressive ataxia, dysarthria, motor dysfunction
- Selective Purkinje cell degeneration
- PolyQ expansion causes:
- Altered protein conformation
- Aberrant interactions
- Transcriptional dysregulation
- Mitochondrial dysfunction
- ATXN1 is upregulated in AD brain
- Interacts with BACE1
- May influence Aβ production
- GWAS suggests AD risk association
- ALS: ATXN1 variants modify risk
- FTD: Rare pathogenic variants
| Strategy |
Status |
Notes |
| ASO therapy |
Clinical trials |
Targeting ATXN1 mRNA |
| Peptide inhibitors |
Preclinical |
Block polyQ toxicity |
| Kinase inhibitors |
Research |
S776 phosphorylation modulators |
| Gene therapy |
Preclinical |
CRISPR approaches |
- Orr et al. (1993) "Expansion of an unstable trinucleotide CAG repeat in spinocerebellar ataxia type 1" Nat Genet[1]
- Zoghbi & Orr (2009) "Polyglutamine diseases: where does toxicity come from?" Neuron[2]
The polyglutamine expansion in ATXN1 leads to toxic gain-of-function:
- Nuclear aggregation: Mutant ataxin-1 forms nuclear inclusions
- Transcriptional dysregulation: Interferes with gene expression programs
- RNA toxicity: Bidirectional transcription produces toxic species
- Interaction disruption: Alters normal protein-protein interactions[^1]
| Approach |
Description |
Status |
| ASOs |
Antisense oligonucleotides targeting ATXN1 |
Preclinical |
| Small molecules |
Aggregate modifiers |
Research |
| Gene editing |
CRISPR approaches |
Research |
The polyglutamine expansion in ATXN1 leads to toxic gain-of-function:
- Nuclear aggregation: Mutant ataxin-1 forms nuclear inclusions
- Transcriptional dysregulation: Interferes with gene expression programs
- RNA toxicity: Bidirectional transcription produces toxic species
- Interaction disruption: Alters normal protein-protein interactions[^1]
| Approach |
Description |
Status |
| ASOs |
Antisense oligonucleotides targeting ATXN1 |
Preclinical |
| Small molecules |
Aggregate modifiers |
Research |
| Gene editing |
CRISPR approaches |
Research |
The polyglutamine expansion in ATXN1 leads to toxic gain-of-function:
- Nuclear aggregation: Mutant ataxin-1 forms nuclear inclusions
- Transcriptional dysregulation: Interferes with gene expression programs
- RNA toxicity: Bidirectional transcription produces toxic species
- Interaction disruption: Alters normal protein-protein interactions[^1]
| Approach |
Description |
Status |
| ASOs |
Antisense oligonucleotides targeting ATXN1 |
Preclinical |
| Small molecules |
Aggregate modifiers |
Research |
| Gene editing |
CRISPR approaches |
Research |
Ataxin-1 (encoded by ATXN1) is a nuclear RNA-binding protein involved in transcriptional regulation and RNA processing. The protein contains:
- AXH domain for homodimerization and transcription factor binding
- Polyglutamine (polyQ) tract
- Nuclear localization signal
- Phosphorylation sites that modulate toxicity
Normal ataxin-1 functions include:
- Transcriptional co-activation through interaction with transcription factors
- Alternative splicing regulation
- Neuronal development and synaptic plasticity
- Stress response pathways
SCA1 is caused by CAG repeat expansion in the ATXN1 gene (>41 repeats), leading to:
- Progressive cerebellar ataxia and incoordination
- Dysarthria and dysphagia
- Peripheral neuropathy
- Cognitive decline in advanced disease
- Characteristic Purkinje cell degeneration
The pathogenesis involves:
- Toxic gain-of-function from expanded polyQ tract
- Transcriptional dysregulation of neuronal genes
- Disruption of RNA processing
- Mitochondrial dysfunction
- Impaired autophagy
Current research focuses on:
- ASOs targeting mutant ATXN1 mRNA for degradation
- CRISPR-based gene editing to correct repeat expansion
- Modulators of ataxin-1 phosphorylation (e.g., S776 phosphorylation site)
- Histone deacetylase (HDAC) inhibitors for transcriptional dysfunction
- Neuroprotective agents to slow Purkinje cell degeneration
- Gene therapy approaches for protein replacement
The study of Ataxin 1 Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Orr HT. (2012). 'Spinocerebellar ataxia type 1.' Handbook of Clinical Neurology. PMID:21827903
- Zoghbi HY, et al. (2015). 'ATXN1 and SCA1.' Nature Reviews Neurology. PMID:26103237
- Serra HG, et al. (2006). 'Ataxin-1 function in the cerebellum.' Journal of Neuroscience. PMID:16525063
- Lim J, et al. (2008). 'Opposing effects of polyglutamine expansion.' Nature. PMID:18815595
Ataxin-1 (encoded by ATXN1) is a nuclear RNA-binding protein involved in transcriptional regulation and RNA processing. The protein contains:
- AXH domain for homodimerization and transcription factor binding
- Polyglutamine (polyQ) tract
- Nuclear localization signal
- Phosphorylation sites that modulate toxicity
Normal ataxin-1 functions include:
- Transcriptional co-activation through interaction with transcription factors
- Alternative splicing regulation
- Neuronal development and synaptic plasticity
- Stress response pathways
SCA1 is caused by CAG repeat expansion in the ATXN1 gene (>41 repeats), leading to:
- Progressive cerebellar ataxia and incoordination
- Dysarthria and dysphagia
- Peripheral neuropathy
- Cognitive decline in advanced disease
- Characteristic Purkinje cell degeneration
The pathogenesis involves:
- Toxic gain-of-function from expanded polyQ tract
- Transcriptional dysregulation of neuronal genes
- Disruption of RNA processing
- Mitochondrial dysfunction
- Impaired autophagy
Current research focuses on:
- ASOs targeting mutant ATXN1 mRNA for degradation
- CRISPR-based gene editing to correct repeat expansion
- Modulators of ataxin-1 phosphorylation (e.g., S776 phosphorylation site)
- Histone deacetylase (HDAC) inhibitors for transcriptional dysfunction
- Neuroprotective agents to slow Purkinje cell degeneration
- Gene therapy approaches for protein replacement
- Orr HT. (2012). 'Spinocerebellar ataxia type 1.' Handbook of Clinical Neurology. PMID:21827903
- Zoghbi HY, et al. (2015). 'ATXN1 and SCA1.' Nature Reviews Neurology. PMID:26103237
- Serra HG, et al. (2006). 'Ataxin-1 function in the cerebellum.' Journal of Neuroscience. PMID:16525063
- Lim J, et al. (2008). 'Opposing effects of polyglutamine expansion.' Nature. PMID:18815595
The polyglutamine expansion in ATXN1 leads to toxic gain-of-function:
- Nuclear aggregation: Mutant ataxin-1 forms nuclear inclusions
- Transcriptional dysregulation: Interferes with gene expression programs
- RNA toxicity: Bidirectional transcription produces toxic species
- Interaction disruption: Alters normal protein-protein interactions[^1]
| Approach |
Description |
Status |
| ASOs |
Antisense oligonucleotides targeting ATXN1 |
Preclinical |
| Small molecules |
Aggregate modifiers |
Research |
| Gene editing |
CRISPR approaches |
Research |
Ataxin-1 (encoded by ATXN1) is a nuclear RNA-binding protein involved in transcriptional regulation and RNA processing. The protein contains:
- AXH domain for homodimerization and transcription factor binding
- Polyglutamine (polyQ) tract
- Nuclear localization signal
- Phosphorylation sites that modulate toxicity
Normal ataxin-1 functions include:
- Transcriptional co-activation through interaction with transcription factors
- Alternative splicing regulation
- Neuronal development and synaptic plasticity
- Stress response pathways
SCA1 is caused by CAG repeat expansion in the ATXN1 gene (>41 repeats), leading to:
- Progressive cerebellar ataxia and incoordination
- Dysarthria and dysphagia
- Peripheral neuropathy
- Cognitive decline in advanced disease
- Characteristic Purkinje cell degeneration
The pathogenesis involves:
- Toxic gain-of-function from expanded polyQ tract
- Transcriptional dysregulation of neuronal genes
- Disruption of RNA processing
- Mitochondrial dysfunction
- Impaired autophagy
Current research focuses on:
- ASOs targeting mutant ATXN1 mRNA for degradation
- CRISPR-based gene editing to correct repeat expansion
- Modulators of ataxin-1 phosphorylation (e.g., S776 phosphorylation site)
- Histone deacetylase (HDAC) inhibitors for transcriptional dysfunction
- Neuroprotective agents to slow Purkinje cell degeneration
- Gene therapy approaches for protein replacement
- Orr HT. (2012). 'Spinocerebellar ataxia type 1.' Handbook of Clinical Neurology. PMID:21827903
- Zoghbi HY, et al. (2015). 'ATXN1 and SCA1.' Nature Reviews Neurology. PMID:26103237
- Serra HG, et al. (2006). 'Ataxin-1 function in the cerebellum.' Journal of Neuroscience. PMID:16525063
- Lim J, et al. (2008). 'Opposing effects of polyglutamine expansion.' Nature. PMID:18815595
Ataxin-1 (encoded by ATXN1) is a nuclear RNA-binding protein involved in transcriptional regulation and RNA processing. The protein contains:
- AXH domain for homodimerization and transcription factor binding
- Polyglutamine (polyQ) tract
- Nuclear localization signal
- Phosphorylation sites that modulate toxicity
Normal ataxin-1 functions include:
- Transcriptional co-activation through interaction with transcription factors
- Alternative splicing regulation
- Neuronal development and synaptic plasticity
- Stress response pathways
SCA1 is caused by CAG repeat expansion in the ATXN1 gene (>41 repeats), leading to:
- Progressive cerebellar ataxia and incoordination
- Dysarthria and dysphagia
- Peripheral neuropathy
- Cognitive decline in advanced disease
- Characteristic Purkinje cell degeneration
The pathogenesis involves:
- Toxic gain-of-function from expanded polyQ tract
- Transcriptional dysregulation of neuronal genes
- Disruption of RNA processing
- Mitochondrial dysfunction
- Impaired autophagy
Current research focuses on:
- ASOs targeting mutant ATXN1 mRNA for degradation
- CRISPR-based gene editing to correct repeat expansion
- Modulators of ataxin-1 phosphorylation (e.g., S776 phosphorylation site)
- Histone deacetylase (HDAC) inhibitors for transcriptional dysfunction
- Neuroprotective agents to slow Purkinje cell degeneration
- Gene therapy approaches for protein replacement
- Orr HT. (2012). 'Spinocerebellar ataxia type 1.' Handbook of Clinical Neurology. PMID:21827903
- Zoghbi HY, et al. (2015). 'ATXN1 and SCA1.' Nature Reviews Neurology. PMID:26103237
- Serra HG, et al. (2006). 'Ataxin-1 function in the cerebellum.' Journal of Neuroscience. PMID:16525063
- Lim J, et al. (2008). 'Opposing effects of polyglutamine expansion.' Nature. PMID:18815595
The polyglutamine expansion in ATXN1 leads to toxic gain-of-function:
- Nuclear aggregation: Mutant ataxin-1 forms nuclear inclusions
- Transcriptional dysregulation: Interferes with gene expression programs
- RNA toxicity: Bidirectional transcription produces toxic species
- Interaction disruption: Alters normal protein-protein interactions[^1]
| Approach |
Description |
Status |
| ASOs |
Antisense oligonucleotides targeting ATXN1 |
Preclinical |
| Small molecules |
Aggregate modifiers |
Research |
| Gene editing |
CRISPR approaches |
Research |
The polyglutamine expansion in ATXN1 leads to toxic gain-of-function:
- Nuclear aggregation: Mutant ataxin-1 forms nuclear inclusions
- Transcriptional dysregulation: Interferes with gene expression programs
- RNA toxicity: Bidirectional transcription produces toxic species
- Interaction disruption: Alters normal protein-protein interactions[^1]
| Approach |
Description |
Status |
| ASOs |
Antisense oligonucleotides targeting ATXN1 |
Preclinical |
| Small molecules |
Aggregate modifiers |
Research |
| Gene editing |
CRISPR approaches |
Research |
Ataxin-1 (encoded by ATXN1) is a nuclear RNA-binding protein involved in transcriptional regulation and RNA processing. The protein contains:
- AXH domain for homodimerization and transcription factor binding
- Polyglutamine (polyQ) tract
- Nuclear localization signal
- Phosphorylation sites that modulate toxicity
Normal ataxin-1 functions include:
- Transcriptional co-activation through interaction with transcription factors
- Alternative splicing regulation
- Neuronal development and synaptic plasticity
- Stress response pathways
SCA1 is caused by CAG repeat expansion in the ATXN1 gene (>41 repeats), leading to:
- Progressive cerebellar ataxia and incoordination
- Dysarthria and dysphagia
- Peripheral neuropathy
- Cognitive decline in advanced disease
- Characteristic Purkinje cell degeneration
The pathogenesis involves:
- Toxic gain-of-function from expanded polyQ tract
- Transcriptional dysregulation of neuronal genes
- Disruption of RNA processing
- Mitochondrial dysfunction
- Impaired autophagy
Current research focuses on:
- ASOs targeting mutant ATXN1 mRNA for degradation
- CRISPR-based gene editing to correct repeat expansion
- Modulators of ataxin-1 phosphorylation (e.g., S776 phosphorylation site)
- Histone deacetylase (HDAC) inhibitors for transcriptional dysfunction
- Neuroprotective agents to slow Purkinje cell degeneration
- Gene therapy approaches for protein replacement
- Orr HT. (2012). 'Spinocerebellar ataxia type 1.' Handbook of Clinical Neurology. PMID:21827903
- Zoghbi HY, et al. (2015). 'ATXN1 and SCA1.' Nature Reviews Neurology. PMID:26103237
- Serra HG, et al. (2006). 'Ataxin-1 function in the cerebellum.' Journal of Neuroscience. PMID:16525063
- Lim J, et al. (2008). 'Opposing effects of polyglutamine expansion.' Nature. PMID:18815595
Ataxin-1 (encoded by ATXN1) is a nuclear RNA-binding protein involved in transcriptional regulation and RNA processing. The protein contains:
- AXH domain for homodimerization and transcription factor binding
- Polyglutamine (polyQ) tract
- Nuclear localization signal
- Phosphorylation sites that modulate toxicity
Normal ataxin-1 functions include:
- Transcriptional co-activation through interaction with transcription factors
- Alternative splicing regulation
- Neuronal development and synaptic plasticity
- Stress response pathways
SCA1 is caused by CAG repeat expansion in the ATXN1 gene (>41 repeats), leading to:
- Progressive cerebellar ataxia and incoordination
- Dysarthria and dysphagia
- Peripheral neuropathy
- Cognitive decline in advanced disease
- Characteristic Purkinje cell degeneration
The pathogenesis involves:
- Toxic gain-of-function from expanded polyQ tract
- Transcriptional dysregulation of neuronal genes
- Disruption of RNA processing
- Mitochondrial dysfunction
- Impaired autophagy
Current research focuses on:
- ASOs targeting mutant ATXN1 mRNA for degradation
- CRISPR-based gene editing to correct repeat expansion
- Modulators of ataxin-1 phosphorylation (e.g., S776 phosphorylation site)
- Histone deacetylase (HDAC) inhibitors for transcriptional dysfunction
- Neuroprotective agents to slow Purkinje cell degeneration
- Gene therapy approaches for protein replacement
- Orr HT. (2012). 'Spinocerebellar ataxia type 1.' Handbook of Clinical Neurology. PMID:21827903
- Zoghbi HY, et al. (2015). 'ATXN1 and SCA1.' Nature Reviews Neurology. PMID:26103237
- Serra HG, et al. (2006). 'Ataxin-1 function in the cerebellum.' Journal of Neuroscience. PMID:16525063
- Lim J, et al. (2008). 'Opposing effects of polyglutamine expansion.' Nature. PMID:18815595
The polyglutamine expansion in ATXN1 leads to toxic gain-of-function:
- Nuclear aggregation: Mutant ataxin-1 forms nuclear inclusions
- Transcriptional dysregulation: Interferes with gene expression programs
- RNA toxicity: Bidirectional transcription produces toxic species
- Interaction disruption: Alters normal protein-protein interactions[^1]
| Approach |
Description |
Status |
| ASOs |
Antisense oligonucleotides targeting ATXN1 |
Preclinical |
| Small molecules |
Aggregate modifiers |
Research |
| Gene editing |
CRISPR approaches |
Research |
Ataxin-1 (encoded by ATXN1) is a nuclear RNA-binding protein involved in transcriptional regulation and RNA processing. The protein contains:
- AXH domain for homodimerization and transcription factor binding
- Polyglutamine (polyQ) tract
- Nuclear localization signal
- Phosphorylation sites that modulate toxicity
Normal ataxin-1 functions include:
- Transcriptional co-activation through interaction with transcription factors
- Alternative splicing regulation
- Neuronal development and synaptic plasticity
- Stress response pathways
SCA1 is caused by CAG repeat expansion in the ATXN1 gene (>41 repeats), leading to:
- Progressive cerebellar ataxia and incoordination
- Dysarthria and dysphagia
- Peripheral neuropathy
- Cognitive decline in advanced disease
- Characteristic Purkinje cell degeneration
The pathogenesis involves:
- Toxic gain-of-function from expanded polyQ tract
- Transcriptional dysregulation of neuronal genes
- Disruption of RNA processing
- Mitochondrial dysfunction
- Impaired autophagy
Current research focuses on:
- ASOs targeting mutant ATXN1 mRNA for degradation
- CRISPR-based gene editing to correct repeat expansion
- Modulators of ataxin-1 phosphorylation (e.g., S776 phosphorylation site)
- Histone deacetylase (HDAC) inhibitors for transcriptional dysfunction
- Neuroprotective agents to slow Purkinje cell degeneration
- Gene therapy approaches for protein replacement
- Orr HT. (2012). 'Spinocerebellar ataxia type 1.' Handbook of Clinical Neurology. PMID:21827903
- Zoghbi HY, et al. (2015). 'ATXN1 and SCA1.' Nature Reviews Neurology. PMID:26103237
- Serra HG, et al. (2006). 'Ataxin-1 function in the cerebellum.' Journal of Neuroscience. PMID:16525063
- Lim J, et al. (2008). 'Opposing effects of polyglutamine expansion.' Nature. PMID:18815595
Ataxin-1 (encoded by ATXN1) is a nuclear RNA-binding protein involved in transcriptional regulation and RNA processing. The protein contains:
- AXH domain for homodimerization and transcription factor binding
- Polyglutamine (polyQ) tract
- Nuclear localization signal
- Phosphorylation sites that modulate toxicity
Normal ataxin-1 functions include:
- Transcriptional co-activation through interaction with transcription factors
- Alternative splicing regulation
- Neuronal development and synaptic plasticity
- Stress response pathways
SCA1 is caused by CAG repeat expansion in the ATXN1 gene (>41 repeats), leading to:
- Progressive cerebellar ataxia and incoordination
- Dysarthria and dysphagia
- Peripheral neuropathy
- Cognitive decline in advanced disease
- Characteristic Purkinje cell degeneration
The pathogenesis involves:
- Toxic gain-of-function from expanded polyQ tract
- Transcriptional dysregulation of neuronal genes
- Disruption of RNA processing
- Mitochondrial dysfunction
- Impaired autophagy
Current research focuses on:
- ASOs targeting mutant ATXN1 mRNA for degradation
- CRISPR-based gene editing to correct repeat expansion
- Modulators of ataxin-1 phosphorylation (e.g., S776 phosphorylation site)
- Histone deacetylase (HDAC) inhibitors for transcriptional dysfunction
- Neuroprotective agents to slow Purkinje cell degeneration
- Gene therapy approaches for protein replacement
[1] Ataxin-1 polyglutamine toxicity in Alzheimer disease. PMID:21617653
Antisense oligonucleotide (ASO) approaches targeting ATXN1 mRNA have shown promise in preclinical SCA1 models, reducing mutant ataxin-1 levels and improving motor coordination.
CRISPR-Cas9 approaches to correct the ATXN1 repeat expansion are being developed, though delivery to the cerebellum remains challenging.
RNAi-mediated knockdown of mutant ataxin-1 reduces toxicity in cellular models.
- Identification of small molecule ataxin-1 modulators
- Understanding the role of ATXN1 in cerebellar circuit function
- Development of biomarker assays for SCA1 progression